Soleno Therapeutics - The FDA Approval for Vykat XR Represents an Important Milestone!
Reading Time: 1 minute
Business drivers: Soleno Therapeutics (SLNO) specializes in the development of new therapies and medications for rare diseases. With the FDA approval for Vykat XR for the treatment of hyperphagia in patients with Prader-Willi syndrome (PWS) aged 4 years and older in March 2025, Soleno Therapeutics has achieved a significant breakthrough, with analysts estimating the drug's peak annual sales potential to be up to $2 billion. Recently, the pharma company faced notable pressure following the death of a 17-year-old patient. However, Soleno indicated...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
